Criteria defining patients as being in accelerated phase
| Trial no. . | Resistant to therapy . | Spleen size increasing . | Major cytogenetic evolution . | Blasts >10% . | Platelets >1000 × 109/L . | Other (specified) . |
|---|---|---|---|---|---|---|
| 1 | Y | Y | Y | N | N | |
| 2 | Y | Y | NK | N | N | |
| 3 | Y | N | N | N | N | |
| 4 | N | N | N | Y | Y | Anemia |
| 5 | Y | Y | Y | N | N | |
| 6 | Y | Y | N | Y | N | |
| 7 | Y | NK | N | Y | N | |
| 8 | N | Y | Y | N | N | BM fibrosis |
| 9 | Y | Y | N | Y | N | |
| 10 | Y | Y | N | N | N | Anemia |
| 11 | Y | Y | Y | N | N | |
| 12 | Y | N | N | N | Y | Basophils >20% |
| 13 | Y | Y | NK | N | N | |
| 14 | Y | Y | N | N | N | Fever and bone pain |
| 15 | Y | Y | Y | Y | N | |
| 16 | N | N | N | N | Y | |
| 17 | Y | Y | Y | N | N | |
| 18 | N | N | N | N | N | Rising blast count (7.5%) |
| 19 | Y | Y | N | N | Y | |
| 20 | Y | Y | N | Y | N | |
| 21 | Y | Y | N | N | Y | |
| 22 | NK | NK | Y | N | N | Anemia and falling platelet count |
| Trial no. . | Resistant to therapy . | Spleen size increasing . | Major cytogenetic evolution . | Blasts >10% . | Platelets >1000 × 109/L . | Other (specified) . |
|---|---|---|---|---|---|---|
| 1 | Y | Y | Y | N | N | |
| 2 | Y | Y | NK | N | N | |
| 3 | Y | N | N | N | N | |
| 4 | N | N | N | Y | Y | Anemia |
| 5 | Y | Y | Y | N | N | |
| 6 | Y | Y | N | Y | N | |
| 7 | Y | NK | N | Y | N | |
| 8 | N | Y | Y | N | N | BM fibrosis |
| 9 | Y | Y | N | Y | N | |
| 10 | Y | Y | N | N | N | Anemia |
| 11 | Y | Y | Y | N | N | |
| 12 | Y | N | N | N | Y | Basophils >20% |
| 13 | Y | Y | NK | N | N | |
| 14 | Y | Y | N | N | N | Fever and bone pain |
| 15 | Y | Y | Y | Y | N | |
| 16 | N | N | N | N | Y | |
| 17 | Y | Y | Y | N | N | |
| 18 | N | N | N | N | N | Rising blast count (7.5%) |
| 19 | Y | Y | N | N | Y | |
| 20 | Y | Y | N | Y | N | |
| 21 | Y | Y | N | N | Y | |
| 22 | NK | NK | Y | N | N | Anemia and falling platelet count |
Y, yes; N, no; NK, not known; BM, bone marrow.